Twenty-one patients with adrenocortical carcinoma (ACC) diagnosed at three hospitals over a ten-year period were reviewed for clinical and pathologic features that might have therapeutic implications.Depending upon the extent of cellular pleomorphism, ACC could be defined as anaplastic or differentiated. Anaplastic ACC occurred more often in male patients, produced more frequent cutaneous metastases ( P = 0.01), and was associated with a lack of clinical or laboratory evidence of hormone production ( P = 0.01). In contrast, differentiated ACC usually occurred in women and produced clinical or laboratory evidence of hormonal excess. Median survival time of patients with anaplastic ACC was only five months, while median survival time of those with differentiated ACC was 40 months ( P = 0.005). Patients with differentiated ACC survived for long periods, even with metastatic disease. Three of 5 such patients had objective responses to o,p'-DDD (Mitotane) therapy. The histopathology of ACC is an important prognostic factor and should be considered in the design of future therapeutic trials.Cancer 45:2880-2883, 1980. DRENOCORTICAL CARCINOMA (ACC) is a rareA disease and patients are few, even at major cancer center^.^ Clinical experience is therefore relatively limited. Prior studies of the morphology of ACC have focused on the differences between adenomas and carcinomas or the relationship between tumor histopathology and overproduction of h o r m o n e~.~J -'~ Much of this prior work revealed no association between histology or hormone production and clinical behavior.3,4,6,11-14 H owever, our experience with 5 patients with ACC suggested that histopathology and biochemical behavior might be prognostically important. Therefore, 16 additional cases were retrospectively studied. Materials and MethodsEvery patient with ACC seen at each of three hospitals during the period from 1969 through 1978 was reviewed.

Four patients with adrenal cortical carcinoma were treated with standard doses of o,p'-DDD. Plasma levels of o,p'-DDD and its metabolites o,p'-DDA and o,p'-DDE were measured. o,p'-DDD was measurable for up to 8 months after stopping therapy, and trace levels of metabolites were detectable at 18 months. Although 2 of 3 patients with measurable disease had objective tumor response and one patient achieved a complete response, severe drug toxicity occurred in all patients and signs of adrenal insufficiency occurred in three. Low dose therapy with o,p'-DDD is suggested, together with full gluco and mineralocorticoid replacement. Measurement of o,p'-DDD and its metabolites in plasma may prove clinically useful in developing effective but less toxic dosage schedules.

No abstract

Twenty‐five patients with metastatic prostate cancer were treated with a combination of Adriamycin 50 mg/m2 and cis‐platinum (CDDP) 50 mg/m2 every three weeks. Response was evaluated using radioisotope bone scan, serum acid phosphatase levels, and clinical status. Response rates of 6% bone, 21% acid phosphatase, and 24% clinical status were noted. Major toxicity was gastrointestinal (due to CDDP). Treatment was well tolerated even in patients with extensive bone metastases and prior irradiation. Using the response criteria described here, patients with metastatic prostate cancer without measurable soft tissue disease are eligible for Phase II and III study.